HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide

Eitemau Tebyg

• Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro
  gan: Mink, M., et al.
  Cyhoeddwyd: (2005)
• Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors
  gan: Ray, Neelanjana, et al.
  Cyhoeddwyd: (2007)
• Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function
  gan: Eggink, Dirk, et al.
  Cyhoeddwyd: (2011)
• Antibody Neutralization Escape Mediated by Point Mutations in the Intracytoplasmic Tail of Human Immunodeficiency Virus Type 1 gp41
  gan: Kalia, Vandana, et al.
  Cyhoeddwyd: (2005)
• Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations
  gan: Marcial, Michelle, et al.
  Cyhoeddwyd: (2006)